Between 11 January 2018 and 9 December 2020, 5,220 patients were screened of whom 92 were identified to have ROS1-positive, advanced/metastatic NSCLC by liquid biopsies, giving a prevalence of ROS1 fusions of 1.8%. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.